Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer.
Journal
Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
14
08
2020
accepted:
14
01
2021
entrez:
27
2
2021
pubmed:
28
2
2021
medline:
19
4
2022
Statut:
epublish
Résumé
CD4 T cells have been implicated in cancer immunity for their helper functions. Moreover, their direct cytotoxic potential has been shown in some patients with cancer. Here, by mining single-cell RNA-seq datasets, we identified CD4 T cell clusters displaying cytotoxic phenotypes in different human cancers, resembling CD8 T cell profiles. Using the peptide-MHCII-multimer technology, we confirmed ex vivo the presence of cytolytic tumor-specific CD4 T cells. We performed an integrated phenotypic and functional characterization of these cells, down to the single-cell level, through a high-throughput nanobiochip consisting of massive arrays of picowells and machine learning. We demonstrated a direct, contact-, and granzyme-dependent cytotoxic activity against tumors, with delayed kinetics compared to classical cytotoxic lymphocytes. Last, we found that this cytotoxic activity was in part dependent on SLAMF7. Agonistic engagement of SLAMF7 enhanced cytotoxicity of tumor-specific CD4 T cells, suggesting that targeting these cells might prove synergistic with other cancer immunotherapies.
Identifiants
pubmed: 33637530
pii: 7/9/eabe3348
doi: 10.1126/sciadv.abe3348
pmc: PMC7909889
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).
Références
Nat Rev Immunol. 2008 Jul;8(7):523-32
pubmed: 18566595
Front Immunol. 2016 Mar 09;7:93
pubmed: 27014272
J Immunol. 1991 May 1;146(9):3242-9
pubmed: 1673149
Oncoimmunology. 2016 Sep 9;5(10):e1216290
pubmed: 27853637
Nat Immunol. 2005 Dec;6(12):1236-44
pubmed: 16273099
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
J Clin Oncol. 2017 Oct 10;35(29):3322-3329
pubmed: 28809608
Nucleic Acids Res. 2019 Jan 8;47(D1):D330-D338
pubmed: 30395331
J Virol. 2015 Oct 21;90(2):650-8
pubmed: 26491148
Arthritis Res Ther. 2003;5(5):R292-300
pubmed: 12932293
Arthritis Rheumatol. 2018 Jul;70(7):1133-1143
pubmed: 29499100
J Vis Exp. 2013 Feb 02;(72):e50058
pubmed: 23407457
Oncoimmunology. 2012 Sep 1;1(6):908-916
pubmed: 23162758
Cell. 2018 Nov 1;175(4):998-1013.e20
pubmed: 30388456
J Exp Med. 2009 Jan 16;206(1):51-9
pubmed: 19139168
Science. 2015 Dec 11;350(6266):1387-90
pubmed: 26516200
JCI Insight. 2020 Feb 27;5(4):
pubmed: 32102981
Nature. 2017 Jul 13;547(7662):217-221
pubmed: 28678778
Cell. 2018 Aug 23;174(5):1293-1308.e36
pubmed: 29961579
J Immunol. 2011 Oct 1;187(7):3555-64
pubmed: 21880986
J Immunol. 2002 Jun 1;168(11):5954-8
pubmed: 12023402
Cancer Res. 2017 Apr 1;77(7):1623-1636
pubmed: 28104684
JCI Insight. 2017 Jul 20;2(14):
pubmed: 28724801
Nature. 2017 Apr 13;544(7649):250-254
pubmed: 28371798
Nat Immunol. 2013 Mar;14(3):271-80
pubmed: 23334789
Sci Rep. 2019 Aug 23;9(1):12308
pubmed: 31444380
Curr Opin Immunol. 2016 Apr;39:44-51
pubmed: 26796069
Clin Exp Immunol. 2004 Oct;138(1):10-3
pubmed: 15373899
Science. 2014 May 9;344(6184):641-5
pubmed: 24812403
J Exp Med. 2016 Jan 11;213(1):123-38
pubmed: 26694968
Cancer Immunol Res. 2013 Oct;1(4):235-44
pubmed: 24396833
PLoS Pathog. 2016 Sep 23;12(9):e1005839
pubmed: 27662621
Bioinformatics. 2015 Oct 1;31(19):3189-97
pubmed: 26059718
Int J Clin Exp Pathol. 2015 Mar 01;8(3):2627-37
pubmed: 26045768
J Exp Med. 2010 Mar 15;207(3):651-67
pubmed: 20156973
Immunity. 2020 Jan 14;52(1):151-166.e6
pubmed: 31924474
Am J Cancer Res. 2017 Aug 01;7(8):1637-1641
pubmed: 28861320
Elife. 2018 Feb 28;7:
pubmed: 29488879
J Clin Virol. 2019 Oct;119:17-23
pubmed: 31445411
Eur J Immunol. 2009 Aug;39(8):2076-82
pubmed: 19672903
Nat Neurosci. 2018 Sep;21(9):1281-1289
pubmed: 30127430
J Immunol. 2007 Mar 15;178(6):3566-74
pubmed: 17339453
Nat Commun. 2018 Mar 15;9(1):1092
pubmed: 29545564
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16916-21
pubmed: 20837541
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Front Immunol. 2017 Sep 20;8:1160
pubmed: 28979263
Sci Transl Med. 2018 Jul 18;10(450):
pubmed: 30021886
J Exp Med. 2010 Mar 15;207(3):637-50
pubmed: 20156971
J Immunol. 2004 Aug 1;173(3):1834-41
pubmed: 15265915
Nature. 2015 Apr 30;520(7549):692-6
pubmed: 25901682
Cell. 2017 Dec 14;171(7):1611-1624.e24
pubmed: 29198524
J Exp Med. 2015 Aug 24;212(9):1405-14
pubmed: 26216123
Nat Med. 2015 Jan;21(1):81-5
pubmed: 25531942
Sci Rep. 2017 Apr 28;7(1):1288
pubmed: 28455530
Cell. 2020 Jun 25;181(7):1612-1625.e13
pubmed: 32497499
Haematologica. 2004 Apr;89(4):435-43
pubmed: 15075077
Cell. 2017 Jun 15;169(7):1342-1356.e16
pubmed: 28622514
Cell Rep. 2015 Jun 9;11(9):1474-85
pubmed: 26027932
Front Immunol. 2017 Mar 24;8:325
pubmed: 28392788
J Exp Med. 2012 Oct 22;209(11):2113-26
pubmed: 23008334
Clin Cancer Res. 2019 Apr 15;25(8):2392-2402
pubmed: 30463850
Mol Cell Biol. 2015 Jan;35(1):41-51
pubmed: 25312647
J Exp Med. 1990 Nov 1;172(5):1353-7
pubmed: 2146361
Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):E4256-63
pubmed: 26195744
J Immunol. 2016 Jan 1;196(1):484-92
pubmed: 26608920
Sci Immunol. 2018 Jan 19;3(19):
pubmed: 29352091
Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10985-90
pubmed: 16832064
Vaccine. 2016 Oct 17;34(44):5251-5261
pubmed: 27639281
J Clin Invest. 2020 May 1;130(5):2451-2464
pubmed: 31990684
Cell. 2018 Feb 22;172(5):1022-1037.e14
pubmed: 29429633
N Engl J Med. 2008 Jun 19;358(25):2698-703
pubmed: 18565862